JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online October 16, 2008, 10.2967/jnumed.108.052928
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iagaru, A.
Right arrow Articles by Goris, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iagaru, A.
Right arrow Articles by Goris, M. L.

90Y-Ibritumomab Therapy in Refractory Non-Hodgkin's Lymphoma: Observations from 111In-Ibritumomab Pretreatment Imaging

Andrei Iagaru1, Sanjiv Sam Gambhir2 and Michael L. Goris3

1 Division of Nuclear Medicine, Stanford University Medical Center, Stanford, California; 2 Departments of Radiology and Bioengineering, Molecular Imaging Program at Stanford (MIPS), Stanford University School of Medicine, James H. Clark Center, Stanford, California; and 3 Division of Nuclear Medicine, Stanford University Medical Center, Stanford, California


Figure 1
View larger version (84K):
[in this window]
[in a new window]

  		FIGURE 1.  A 60-y-old woman with NHL and complete response after 90Y-ibritumomab treatment. (A) No lesions are seen on anterior whole-body planar pretherapy 111In-ibritumomab scan (images from 48-h scan are shown). (B) Pretherapy (1 mo) MIP image of 18F FDG PET shows abdominal lesions (arrowheads). (C) MIP image of 18F FDG PET after therapy (3 mo) is negative for active disease.

 

Figure 2
View larger version (83K):
[in this window]
[in a new window]

  		FIGURE 2.  A 45-y-old man with NHL and progressive disease after 90Y-ibritumomab treatment. (A) Lesions are seen in abdominal region (arrowheads) on anterior whole-body planar pretherapy 111In-ibritumomab scan (images from 48-h scan are shown). (B and C) Pretherapy (1 mo) MIP image of 18F FDG PET (B) and posttherapy (4 mo) MIP of 18F FDG PET (4 mo apart) (C) show progression of lesions noted before therapy (arrowheads).

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2008 by the Society of Nuclear Medicine.